Safety and Efficacy of Olaparib Alone Or in Combination with Medication Targeting DNA Damaging Repair for Metastatic Triple Negative Breast Cancer

About the Study

The purpose of this study is to learn the safety and effectiveness of the PARP inhibitor, olaparib as a single drug therapy compared with olaparib in combination with the new agent AZD6738 in patients with metastatic Triple-Negative Breast Cancer (TNBC).  NOTE: This study is no longer enrolling people. 

Type of Study

This is a randomized, two-arm, open label study.  

• This is a randomized study, which means that participants will be placed into one of the two treatment groups by chance. Neither patients nor the research doctor will choose the group participants are placed in. 
• The study has two arms. This means that patients in the study are placed in one of two different groups. One group will received the PARP inhibitor olaparib only and the other group will receive olaparib and AZD6738. 
• The study is open-label. All participating patients will know which group they have been assigned to. 

Participants will have tumor biomarker testing to look for mutations in genes that called "homologous recombination repair" (HRR) pathway genes. Participants will be divided into three groups based on their tumor biomarker test results:

• Group A: Patients with BRCA1 or BRCA2 gene mutations
• Group B: Patients with mutations in any of the other genes involved in the HRR pathway, and no mutation in BRCA1 and no mutation in BRCA2
• Group C: Patients with no detected tumor mutations in any of the HRR genes

What the Study Entails

Eligible patients will be randomly placed in one of two treatment arms:

• Arm 1: Participants will take oral olaparib twice daily in a 28-day cycle
• Arm 2: Participants will take oral olaparib twice daily in a 28-day cycle and on days 1-7, participants will also take AZD6738 orally daily.

Participants will stay on the study until they have progression of their cancer or an adverse event that requires them to end their participation. Participants will be followed for up to 24 months. 

Study Sites: 

NOTE: Additional study sites can be found on clinicaltrials.gov.

For information about participating at all sites, contact AstraZeneca Clinical Study Information Center by email or phone: 1-877-240-9479.

• Alaska
  • Anchorage
• Arizona
  • Gilbert
• California
  • Palm Springs
• Colorado
  • Aurora
• Connecticut
  • New Haven
• Illinois
  • Chicago
• Indiana
  • Munster
• Kentucky
  • Hazard
  • Louisville
• Maryland
  • Baltimore
  • Bethesda
• Missouri
  • Kansas City
• New Jersey
  • Brick
• New York
  • East Setauket
  • Lake Success
  • Mount Kisco
  • Stony Brook
• Ohio
  • Cincinnati
  • Kettering
• Oregon
  • Corvallis
• Tennessee
  • Knoxville
• Texas
  • Dallas
• Washington
  • Olympia

Principal Investigator

Andrew Tutt, MB ChB PhD
Guy's Hospital, Great Maze Pond, London